STANDARD BIOTOOLS INC. LAB

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

At Standard BioTools, Inc. ("Standard BioTools" or the "Company"), we are committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Our established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. We offer a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. With advanced technologies in proteomics and genomics, we empower scientists to gain deeper biological insights, accelerate discoveries, and drive improved health outcomes across diverse therapeutic areas including immunology, oncology, neuroscience, cardiometabolic diseases and more.

Last close 0.61 2026-10-23
Market cap $237.7M 2026-06-30 share count
52-week range 0.59 - 1.72

Valuation FY2025 figures against the last close

P/S2.8x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.20

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • Emea
  • Americas
  • Asia-Pacific
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 Emea, FY2025: 36M (42.2%) 42% Emea Americas, FY2025: 30.6M (35.8%) 36% Americas Asia-Pacific, FY2025: 18.8M (22.0%) 22% Asia-Pacific FY2024 Emea, FY2024: 35.6M (39.2%) 39% Americas, FY2024: 37.4M (41.1%) 41% Asia-Pacific, FY2024: 18M (19.7%) 20% FY2023 Emea, FY2023: 36.2M (34.0%) 34% Americas, FY2023: 46.2M (43.4%) 43% Asia-Pacific, FY2023: 23.9M (22.5%) 23%
Region FY2025FY2024FY2023
Emea $36.0M $35.6M $36.2M
Americas $30.6M $37.4M $46.2M
Asia-Pacific $18.8M $18.0M $23.9M

As the company reported it, from the “Revenue and Geographic Area - Schedule of Disaggregation of Revenue (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $85.3M$91.0M$106.3M$97.9M$130.6M$138.1M$117.2M$113.0M$101.9M$104.4M
Cost of revenue $42.8M$46.1M$55.9M$60.9M——$53.0M$51.3M$50.0M$46.0M
Gross profit $42.5M$44.9M$50.5M$37.1M——$64.3M$61.6M$52.0M$58.4M
R&D $26.0M$28.8M$25.9M$37.4M$37.9M$36.5M$31.6M$30.0M$30.8M$38.4M
SG&A $109.9M$103.1M$87.5M$102.3M$98.9M$97.9M$84.5M$79.8M$79.5M$93.2M
Total operating expenses $152.8M$172.4M$127.0M$153.3M$198.0M$189.2M$169.1M$161.1M$110.3M$131.6M
Operating income -$110.2M-$127.5M-$76.6M-$116.2M-$67.5M-$51.0M-$51.8M-$48.2M-$58.4M-$73.2M
Interest expense ——$4.6M$4.3M$3.8M$3.6M$4.3M$13.9M$5.8M$5.8M
Pre-tax income -$96.7M-$90.4M-$74.2M-$192.9M-$63.7M-$54.1M-$66.7M-$61.4M-$63.8M-$80.2M
Income tax $37.9M$542.0K$452.0K$2.8M$4.4M$1.1M$1.9M$2.4M$3.3M$4.2M
Net income -$74.9M-$138.9M-$74.7M-$190.1M-$59.2M-$53.0M-$64.8M-$59.0M-$60.5M-$76.0M
EPS, basic -0.20-0.52-0.94-2.43-0.78-0.74-0.97———
EPS, diluted -0.20-0.52-0.94-2.43-0.78-0.74-0.97-1.49-1.84-2.62
Shares, diluted (wtd. avg.) 381.6M353.2M79.2M78.3M75.8M72.0M66.8M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $120.9M$166.7M$52.5M$82.3M$29.5M$69.5M$23.7M$95.4M$58.1M$35.0M
Short-term investments $66.7M$126.1M$63.2M$84.5M$0$0$37.0M$0$5.1M$24.4M
Receivables $13.4M$14.7M$19.7M$17.3M$18.3M$25.4M$19.0M$16.7M$15.0M$14.6M
Inventory $20.0M$20.7M$20.5M$21.5M$20.8M$19.7M$13.9M$13.0M$15.1M$20.1M
Total current assets $454.3M$375.9M$158.2M$208.8M$72.1M$117.7M$96.1M$127.1M$94.8M$96.7M
Property, plant and equipment $19.3M$22.8M$24.2M$25.7M$28.0M$17.5M$8.1M$8.8M$12.3M$16.5M
Goodwill —$111.3M$106.3M$106.3M$106.4M$106.6M$104.1M$104.1M$104.1M$104.1M
Other intangibles —$29.0M$1.4M$12.6M$27.9M$40.2M$46.2M$57.4M$68.6M$79.8M
Total assets $567.8M$612.3M$323.1M$390.3M$275.2M$324.8M$264.8M$303.6M$287.4M$306.4M
Accounts payable $5.4M$5.0M$9.2M$7.9M$10.6M$9.2M$5.2M$4.0M$4.2M$4.0M
Total current liabilities $108.3M$65.9M$109.3M$43.4M$49.6M$54.2M$32.8M$37.6M$33.5M$29.5M
Long-term debt —$299.0K$63.5M$64.9M——————
Total liabilities $143.5M$140.6M$159.9M$160.5M$180.6M$185.7M$111.2M$231.5M$256.4M$253.2M
Retained earnings -$1.26B-$1.19B-$1.00B-$926.1M-$736.0M-$676.8M-$623.6M-$558.9M-$500.2M-$439.5M
Total equity $424.3M$471.7M-$148.1M-$81.5M$94.6M$139.1M$153.6M$72.1M$30.9M$53.2M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$74.3M-$143.5M-$43.3M-$89.4M-$44.1M-$15.4M-$35.2M-$25.2M-$24.1M-$39.1M
Depreciation and amortisation $9.3M$12.5M$4.0M$3.5M$3.2M$4.0M$4.6M$5.4M$7.4M$6.7M
Stock-based compensation $29.6M$31.7M$13.1M$14.9M$16.1M$14.5M$11.4M$11.0M$9.1M$13.9M
Capital expenditure $8.3M$8.4M$2.8M$3.8M$13.3M$12.7M$2.5M$372.0K$1.6M$5.1M
Investing cash flow $27.4M$363.2M$20.2M-$88.1M-$11.9M$40.0M-$39.3M$4.7M$17.7M$45.1M
Financing cash flow $570.0K-$102.6M-$6.8M$230.8M$16.0M$20.9M$2.8M$57.7M$29.0M$116.0K
Buybacks $0$40.5M$5.4M$563.0K$0—————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-017100.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M -100M 0 100M 200M Revenue, FY2016: 104.4M Gross profit, FY2016: 58.4M Net income, FY2016: -76M Revenue, FY2017: 101.9M Gross profit, FY2017: 52M Net income, FY2017: -60.5M Revenue, FY2018: 113M Gross profit, FY2018: 61.6M Net income, FY2018: -59M Revenue, FY2019: 117.2M Gross profit, FY2019: 64.3M Net income, FY2019: -64.8M Revenue, FY2020: 138.1M Net income, FY2020: -53M Revenue, FY2021: 130.6M Net income, FY2021: -59.2M Revenue, FY2022: 97.9M Gross profit, FY2022: 37.1M Net income, FY2022: -190.1M Revenue, FY2023: 106.3M Gross profit, FY2023: 50.5M Net income, FY2023: -74.7M Revenue, FY2024: 91M Gross profit, FY2024: 44.9M Net income, FY2024: -138.9M Revenue, FY2025: 85.3M Gross profit, FY2025: 42.5M Net income, FY2025: -74.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $104.4M $101.9M $113.0M $117.2M $138.1M $130.6M $97.9M $106.3M $91.0M $85.3M
Gross profit $58.4M $52.0M $61.6M $64.3M — — $37.1M $50.5M $44.9M $42.5M
Net income -$76.0M -$60.5M -$59.0M -$64.8M -$53.0M -$59.2M -$190.1M -$74.7M -$138.9M -$74.9M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Regulation FD disclosure Item 7.01
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement signed Item 1.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Change of control Control of the company has changed hands. Item 5.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%